Ledipasvir And Sofosbuvir Tablet, Film Coated
Product Images NDC 72626-2601

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Ledipasvir And Sofosbuvir (NDC 72626-2601). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asegua Therapeutics Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Ledipasvir 01)

Chemical structure diagram of the active ingredients ledipasvir and sofosbuvir, showing the molecular arrangement and bonds of the combined compounds used in the medication.*

FDA Label Image

Chemical Structure (Ledipasvir 02)

Chemical structure diagram of Sofosbuvir, one of the active ingredients in the drug combination Ledipasvir and Sofosbuvir.*

FDA Label Image

Principal Display Panel (14 Tablet Blister Pack Card Carton)

Packaging label for Ledipasvir and Sofosbuvir 90 mg / 400 mg tablets, oral film-coated dosage form, by Asegua Therapeutics LLC. The label indicates the product is prescription only and comes in two blister cards, each containing 14 tablets. It also notes this is an authorized generic of Harvoni.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.